Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized Antiemetic Regimen Based on Pharmacogenetic Profile in Chinese Breast Cancer Patients
NCT07455955Phase 2Recruiting
- Sponsor
- The Chinese University of Hong Kong
- Start
- Mar 2026
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of olanzapine in chemotherapy-induced nausea and vomiting (CINV), sponsored by The Chinese University of Hong Kong. Primary endpoint: Complete Protection at 2 years. Started Mar 2026; status: recruiting.
02
Drugs
olanzapine
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on NCT07455955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07455955.